Matica Approves Final Plans to Include Increased Production Capacity

June 22, 2017 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to report that the management of Matica and RoyalMax Biotechnology Canada Inc. (“RoyalMax”) have met with the general contractor, the subcontractors, and other consultants at the Dorval facility. In late May, Health Canada announced improvements to the ACMPR application process to permit licensed producers to manage production on the basis of their vault capacity. Matica and RoyalMax have doubled the designed vault size to accommodate a significant increase in our production capacity.

With the new improvements to the ACMPR application process, the stages of the process have been altered.  The pre-license inspection stage has been removed and the license to produce is now issued upon confirmation of completion of the facility. Matica and RoyalMax have now completed the final preparations required for the completion of the Dorval facility.


For more information on Matica please visit the website at:

On behalf of the Board of Directors


/s/Boris Ziger

Boris Ziger, CEO & Chairman


The Company’s filings are available for review at and

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935




Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at

The CSE has not reviewed, approved or disapproved the content of this press release.